Drug intelligence / Profile preview

GS-9911

Development stage: Phase 1
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

GS-9911 is an orally bioavailable small molecule inhibitor of diacylglycerol kinase alpha (DGKα), developed by Gilead Sciences under license from Carna Biosciences. Its mechanism of action involves inhibiting DGKα, which enhances cytotoxic T cell activity and has potential immune checkpoint inhibitory and antineoplastic effects. By blocking DGKα, GS-9911 aims to potentiate T cell activation and promote immune-mediated tumor killing, making it a candidate for cancer immunotherapy. The drug is currently in Phase 1 clinical trials as monotherapy and in combination with anti-PD-1 monoclonal antibodies for the treatment of advanced solid tumors[1][2][3][5][7].

Other names: DGK-alpha inhibitor GS-9911GS 9911GS9911GS-9911

Targets

DGKA (Diacylglycerol kinase alpha)

Beyond the preview

Go deeper on GS-9911.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-9911.

Explore the full profile